Pharmacy staff characteristics associated with support for pharmacy-based HIV testing

Journal of the American Pharmacists Association

Volumn 52, Issue 4, 2012, Pages 472-479

  Amesty, Silvia ^a,b   Blaney, Shannon ^c   Crawford, Natalie D ^b   Rivera, Alexis V ^b   Fuller, Crystal ^b  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b Mailman School of Public Health   (United States)

^c NEW YORK ACADEMY OF MEDICINE   (United States)

Author keywords

HIV testing; Injection drug users; New York City; Pharmacy services

Indexed keywords

ARTICLE; CROSS-SECTIONAL STUDY; DRUG USE; FEMALE; HIV TEST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; NEIGHBORHOOD; PHARMACIST; PHARMACIST ATTITUDE; PHARMACY; SOCIAL WORK; SYRINGE; VACCINATION; ATTITUDE TO HEALTH; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEALTH PERSONNEL ATTITUDE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; METHODOLOGY; MOLECULAR DIAGNOSIS; PERSONALITY; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL;

ATTITUDE OF HEALTH PERSONNEL; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV; HIV INFECTIONS; HUMANS; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; PERSONALITY; PHARMACISTS; PHARMACY;

EID: 84871864598     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2012.10194     Document Type: Article

References (31)

1. New York Academy of Medicine. New York State Expanded Syringe Access Demonstration Program evaluation: evaluation report to the Governor and the New York State Legislature. New York: New York Academy of Medicine; 2003.
2. Fuller CM, Ahern J, Vadnai L, et al. Impact of increased syringe access: preliminary findings on injection drug user syringe source, disposal, and pharmacy sales in Harlem, New York. J Am Pharm Assoc. 2002;42(suppl 2):S77-82.
3. Deren S, Fuller CM, Pouget ER, et al. Impact of expanding syringe access in New York on sources of syringes for injection drug users in Harlem and the Bronx, NYC, USA. Int J Drug Policy. 2003;14:373-9.
4. Birkhead GS, Klein SJ, Candelas AR, et al. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach. Int J Drug Policy. 2007;18:417-25.
5. Platt L, Vickerman P, Collumbien M, et al. Prevalence of HIV, HCV and sexually transmitted infections among injecting drug users in Rawalpindi and Abbottabad, Pakistan: evidenc- for an emerging injection-related HIV epidemic. Sex Transm Infect. 2009;85(suppl 2):17-22.
6. Des Jarlais DC, Arasteh K, Hagan H, et al. Persistence and change in disparities in HIV infection among injection drug users in New York City after large-scale syringe exchange programs. Am J Public Health. 2009;99:S445-51.
7. Fuller CM, Galea S, Caceres W, et al. Multilevel community-based intervention to increase access to sterile syringes among injection drug users through pharmacy sales in New York City. Am J Public Health. 2007;97:117-24.
8. Pouget ER, Deren S, Fuller CM, et al. Receptive syringe sharing among injection drug users in Harlem and the Bronx during the New York State Expanded Syringe Access Demonstration Program. J Acquir Immune Defic Syndr. 2005;39:471-7.
9. Hagan H, Thiede H. Changes in injection risk behavior associated with participation in the Seattle needle-exchange program. J Urban Health. 2000;77:369-82.
10. Groseclose SL, Weinstein B. Impact of increased legal access to needles and syringes on practices of injecting-drug users and police officers, Connecticut, 1992-1993. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10:71-2.
11. Institute of Medicine. Preventing HIV infection among injection drug users in high-risk countries: an assessment of the evidence. Washington, DC: Institute of Medicine; 2006.
12. New York State Expanded Syringe Access Program insert. Accessed at www.health.state.ny.us/publications/9359.pdf, February 10, 2011.
13. Fuller CM, Borrell LN, Latkin CA, et al. Effects of race, neighborhood, and social network on age at initiation of injection drug use. Am J Public Health. 2005;95:689-95.
14. Zaller N, Jeronimo A, Bratberg J, et al. Pharmacist and pharmacy staff experiences with non-prescription (NP) sale of syringes and attitudes toward providing HIV prevention services for injection drug users (IDUs) in Providence, RI. J Urban Health. 2010;87:942-5.
15. Centers for Disease Control and Prevention. HIV transmission rates in the United States. Accessed at www.cdc.gov/hiv/topics/surveillance/resources/ factsheets/transmission.htm, October 31, 2010.
16. Centers for Disease Control and Prevention. Racial/ethnic disparities in diagnoses of HIV/AIDS: 33 states, 2001-2004. MMWR Morb Mortal Wkly Rep. 2006;55:121-5.
17. Centers for Disease Control and Prevention. HIV in the United States. Accessed at www.cdc.gov/hiv/resources/factsheets/us.htm, October 30, 2010.
18. Glynn R, Rhodes P. Estimated HIV prevalence in the United States at the end of 2003. Proceedings of the National HIV Prevention Conference, Atlanta, GA, June 12, 2005.
19. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr. 2005;39:446-53.
20. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS. 2006;20:1447-50.
21. New York City Department of Health and Mental Hygiene. HIV epidemiology and field services: surveillance slide sets. Accessed at www.nyc.gov/html/doh/ html/dires/epi-surveillance.shtml, February 19, 2010.
22. Grygorian A, Hall HI, Durant T, Wei X. Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 U.S. states, 1996-2004. PLoS One. 2009;4(2):e445.
23. Molitor F, Kuenneth C, Waltermeyer J, et al. Linking HIV-infected persons of color and injection drug users to HIV medical and other services: the California Bridge Project. AIDS Patient Care STDS. 2005;19:406-12.
24. McCoy CB, Metsch LR, Chitwood DD, Miles C. Drug use and barriers to use of health care services. Subst Use Misuse. 2001;36:789-806.
25. Bond L, Lauby J, Batson H. HIV testing and the role of individual- and structural-level barriers and facilitators. AIDS Care. 2005;17:125-40.
26. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55:1-17.
27. Rivera AV, Blaney S, Crawford ND, et al. Individual- and neighborhood-level factors associated with nonprescription counseling in pharmacies participating in the New York State Expanded Syringe Access Program. J Am Pharm Assoc. 2010;50:580-7.
28. Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
29. Amesty S, Rivera A, Blaney S, Fuller C. Predictors of discussing HIV testing with customers among pharmacy staff registered in the New York State Expanded Syringe Access Program: preliminary findings from the Pharmacies as Resources Making Links to HIV Testing (PHARM-HIV) study. Accessed at www.hivforum.org/index.php?option=com-content&task=view&id= 352&Itemid=154, February 25, 2011.
30. Rudolph AE, Standish K, Amesty S, et al. A community based approach to linking injection drug users with needed services through pharmacies: an evaluation of a pilot intervention in New York City. AIDS Educ Prev. 2010;22:238-51.
31. Des Jarlais DC, Arasteh K, McKnight C, et al. HIV infection during limited versus combined HIV prevention programs for IDUs in New York City: the importance of transmission behaviors. Drug Alcohol Depend. 2010;109(1-3):154-60.